Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Woodfield

Interventional Cardiology Charleston, SC Medical Doctor

NPI 1568455723 CMS profile 116574

1033 Saint Andrews Blvd, Charleston, SC 29407

Open in the dashboard

General payments

$22,269

915 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,000 paid to institutions, not to them · program year 2019

Through program year 2025, Scott Woodfield of Charleston, SC is reported in the CMS Open Payments database as having received $22,269 across 915 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,293 130
2024 General $5,099 135
2023 General $2,469 115
2022 General $2,548 128
2021 General $3,185 128
2020 General $1,338 85
2019 General $3,337 194

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Woodfield
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Scott Woodfield were reported at $4,293. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Scott Woodfield Interventional Cardiology median Middle half National median
2019 $3,337 $1,097 $329–$3,048 $163
2020 $1,338 $473 $161–$1,480 $114
2021 $3,185 $677 $233–$1,827 $132
2022 $2,548 $978 $333–$2,724 $149
2023 $2,469 $1,136 $382–$2,986 $160
2024 $5,099 $1,181 $395–$3,326 $164
2025 $4,293 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $3,396 75 payments
  2. Boston Scientific Corporation $1,448 42 payments
  3. Cardiovascular Systems Inc. $1,243 18 payments
  4. Amgen Inc. $1,173 89 payments
  5. Janssen Pharmaceuticals, Inc $1,159 89 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $1,018 60 payments
  7. E.R. Squibb & Sons, L.L.C. $984 59 payments
  8. Medtronic, Inc. $906 21 payments
  9. Abbott Laboratories $891 27 payments
  10. AstraZeneca Pharmaceuticals LP $843 57 payments
  11. Other $9,208 378 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,660 908 payments
  2. Travel and Lodging $1,596 6 payments
  3. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,842 18 payments
  2. XARELTO $1,159 89 payments
  3. Repatha $1,141 87 payments
  4. Diamondback Peripheral $1,123 10 payments
  5. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $1,054 38 payments
  6. JARDIANCE $867 52 payments
  7. LifeVest $762 37 payments
  8. ELIQUIS $640 43 payments
  9. CT THROMBECTOMY SYSTEM KIT $620 4 payments
  10. FLOWTRIEVER CATHETER, S $620 4 payments
  11. Other $14,225 653 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

4,040

Median for Cardiology: 2,533

Drug cost

$858,384

Median for Cardiology: $485,213

Branded share of claims

32%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 305 $341,213
Xarelto Rivaroxaban Brand 128 $141,821
Entresto Sacubitril/Valsartan Brand 104 $120,733
Repatha Sureclick Evolocumab Brand 100 $85,205
Jardiance Empagliflozin Brand 37 $36,952
Multaq Dronedarone Hcl Brand 19 $29,908
Praluent Pen Alirocumab Brand 40 $21,865
Droxidopa Generic 11 $13,851
Farxiga Dapagliflozin Propanediol Brand 11 $7,710
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 206 $6,668

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$306,710

Of which drugs: $996

Medicare patients

1,350

Average age 76

Services billed

4,906

650 women, 700 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 51%
Arthritis 51%
Heart failure 43%
Diabetes 39%
Chronic kidney disease 37%
Atrial fibrillation 36%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 30 120 $985

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
$187 305 —
Arcalyst
$135 — —
LEQVIO
$132 — —
Repatha
$117 100 —
JARDIANCE
$101 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

915 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record